Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review

Abstract

BackgroundNovel tuberculosis (TB) drugs and the need to treat drug-resistant tuberculosis (DR-TB) are likely to bring about substantial transformations in TB treatment in coming years. An evidence base for cost and cost-effectiveness analyses of these developments is needed.ObjectiveOur objective was to perform a review of papers assessing provider-incurred as well as patient-incurred costs of treating both drug-susceptible (DS) and multidrug-resistant (MDR)-TB.MethodsFive databases (EMBASE, Medline, the National Health Service Economic Evaluation Database, the Cost-Effectiveness Analysis Registry, and Latin American and Caribbean Health Services Literature) were searched for cost and economic evaluation full-text papers containing primary DS-TB and MDR-TB treatment cost data published in peer-reviewed journals between January 1990 and February 2015. No language restrictions were set. The search terms were a combination of ‘tuberculosis’, ‘multidrug-resistant tuberculosis’, ‘cost’, and ‘treatment’. In the selected papers, study methods and characteristics, quality indicators and costs were extracted into summary tables according to pre-defined criteria. Results were analysed according to country income groups and for provider costs, patient costs and productivity losses. All values were converted to $US, year 2014 values, so that studies could be compared.ResultsWe selected 71 treatment cost papers on DS-TB only, ten papers on MDR-TB only and nine papers that included both DS-TB and MDR-TB. These papers provided evidence on the costs of treating DS-TB and MDR-TB in 50 and 16 countries, respectively. In 31 % of the papers, only provider costs were included; 26 % included only patient-incurred costs, and the remaining 43 % estimated costs incurred by both. From the provider perspective, mean DS-TB treatment costs per patient were US$14,659 in high-income countries (HICs), US$840 in upper middle-income countries (UMICs), US$273 in lower middle-income (LMICs), and US$258 in low-income countries (LICs), showing a strong positive correlation. The respective costs for treating MDR-TB were US$83,365, US$5284, US$6313 and US$1218. Costs incurred by patients when seeking treatment for DS-TB accounted for an additional 3 % of the provider costs in HICs. A greater burden was seen in the other income groups, increasing the costs of DS-TB treatment by 72 % in UMICs, 60 % in LICs and 31 % in LMICs. When provider costs, patient costs and productivity losses were combined, productivity losses accounted for 16 % in HICs, 29 % in UMICs, 40 % in LMICs and 38 % in LICs.ConclusionCost data for MDR-TB treatment are limited, and the variation in delivery mechanisms, as well as the rapidly evolving diagnosis and treatment regimens, means that it is essential to increase the number of studies assessing the cost from both provider and patient perspectives. There is substantial evidence available on the costs of DS-TB treatment from all regions of the world. The patient-incurred costs illustrate that the financial burden of illness is relat...

Tuberculosis care strategies and their economic consequences for patients: the missing link to end tuberculosis

“…While implementation of the Directly Observed, Treatment Short course (DOTS) strategy (1994–2005) and the Stop TB Strategy (2006–2015) had significant contributions to the prevention and control of TB, they were also reported to pose a substantial economic burden on patients in terms of cost and affordability [7–10]. Out-of-Pocket (OOP) payments due to transportation, accommodation and food to get treatment at health facility aggravate economic crisis of TB patients: impacting their adherence to treatment [11–13] and forcing them to stop working, sell their properties, borrow money and reduce their overall income [14–17]. …”

The Impact of Ischemic Stroke on Atrial Fibrillation-Related Healthcare Cost: A Systematic Review

“…Due to the limited information provided in the reviewed studies, it is difficult to further explore the relationship between medical costs and time horizon. Lastly, compared with other costs of illness systematic reviews for AF 13 and other diseases 46,47 …”

Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models

“…We also conducted a systematic review to collate and synthesize unit costs for each country. Empirical TB cost data are limited 20 , and where local values were unavailable we adapted estimates from other settings using local prices, holding country consultations to ensure face validity. We developed country-specific cost models to combine service utilization estimates with unit costs.…”